Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Respiratory Failure, ICU, Asthma (Diagno...
Phase Not Applicable
Enrollment 59
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is an observational study performed by retrospective review of data routinely collected for patients receiving low-flow extracorporeal carbon dioxide removal (ECCO2R) therapy in intensive care units (ICUs). Our aim is to firstly, describe the local practice in terms of patient selection and technical details of clinical management related to the use of low-flow ECCO2R system, and secondly, the clinical results in terms of patient outcomes and adverse events. These findings may allow clinicians to improve the quality and safety of ECCO2R therapy provision in the ICU.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Around 60 participants with respiratory failure as assessed for their clinical characteristics and outcomes (From November 2024 to September 2026 (Anticipated))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 59 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hong Kong University
Contact Information
Study Contact:
Wai Ching Simon Sin, Director, Clinical Professor
(852)9090-8772
drwcsin@hku.hk
SI CHEN, Master
(852)54630558
cyn08ccs@hku.hk
Wai Ching Simon Sin, Director, Clinical Professor
(852) 9090-8772
drwcsin@hku.hk
Queen Mary Hospital (QMH)
Interventions
N/A
Study Locations (1 sites)
Queen Mary Hospital (QMH), Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Patients supported with ECCO2R in one of the designated study sites * Admitted to the ICU between 1 Jan 2022 and 30 June 2024 Exclusion Criteria: * Patients younger than 18 years old
Conditions Severe Asthma
Phase PHASE4
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Adults with severe asthma may have sudden worsening shortness of breath that results in their going to Emergency Department for urgent care. Emergency Room visits for asthma management across Alberta have been reviewed and it has been found that adults frequently need to return for repeated worsening. This is a large drain on health care resources as well as being very distressing for individuals with asthma. Occasionally this results in admission to hospital and rarely may lead to death. People are often treated with steroids to try to prevent the need for Emergency Room visits even though steroid medications have many long term bad side effects. A new medication for patients considered to have severe asthma has been recently approved by Health Canada. This medication, Tezepelumab, is a monthly injection and it helps control asthma in adults regardless of the underlying cause. The study will examine if starting Tezepelumab, compared with a placebo, in the Emergency Room will help settle symptoms of asthma and prevent future worsening requiring repeated Emergency Room visits or the need for courses of outpatient steroid medications.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Tezepelumab — Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60. Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90
  • Drug: Placebo — Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.

Primary Outcomes

  • Proportion of patients who have moderate and severe exacerbations of asthma (90 Days post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-05-11
Completion: 2026-11
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Collaborators: AstraZeneca
Principal Investigators:
  • Irvin Mayers, MD (PRINCIPAL_INVESTIGATOR) - University of Alberta
Contact Information
Study Contact:
Hannah Anstruther, RRT
7804923741
hannahanstruther@ualberta.ca
Amy May, RRT
7804923741
amy.may@ualberta.ca
Amy May, RRT
7804923741
amy.may@ualberta.ca
University of Alberta
Interventions
  • Drug: Tezepelumab — Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60. Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90
  • Drug: Placebo — Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
Study Locations (2 sites)
University of Alberta, Edmonton, Alberta T6G 2G3 Canada
Sturgeon Community Hospital, St. Albert, Alberta T8N6C4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures 2. Female and/or male aged 18 to 55 years 3. History of physician-diagnosed asthma 4. All subjects will have been prescribed high dose inhaled corticosteroid (\> 500 ug fluticasone propionate dry powder formulation equivalents total daily dose. See Appendix C) plus at least one second controller (LABA, LAMA or LTRA) for at least 3 months prior to enrolment. 5. Documented history of at least one moderate or severe asthma exacerbation in the past 12 months 6. Negative pregnancy test (urine or serum) for female subjects of childbearing potential. 7. Female subjects must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of study drug/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used. 8. Subjects who are blood donors should not donate blood during the study and for 3 months following their last dose of study drug. 9. Subject willing and able to comply with study procedures Exclusion Criteria: 1. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) 2. Previous enrolment in the present study 3. Participation in another clinical study with an investigational product during the last 6 months 4. Patients with a known hypersensitivity to Tezepelumab or any of the excipients of the product. 5. Patients who are admitted to hospital at screening. 6. Positive hepatitis C antibody hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening. 7. Known to have tested positive for human immunodeficiency virus 8. Current smokers with a smoking history of \> 10 pack-years. Current smokers with a smoking history of \< 10 pack-years are permitted . Ex-smokers should not have a smoking history \> 10 pack-years at screening. Participants who use e-cigarettes will also be excluded from the study. 9. Known history of drug or alcohol abuse within 1 year of screening 10. Any concomitant medications that are known to be associated with Torsades de Pointes or potent inducers of cytochrome P450 3A4 (CYP3A4). 11. History of QT prolongation associated with other medications that required discontinuation of that medication. 12. Congenital long QT syndrome. 13. Creatinine clearance \<50 ml/min (calculated by Cockcroft-Gault formula, reference Appendix G). 14. For women only - currently pregnant (confirmed with positive pregnancy test) or breast feeding. 15. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
Conditions Parental Anxiety Following Premature Bir...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

In 2018, the World Health Organization (WHO) counted no less than 15 million preterm births each year worldwide, or more than one in ten children. In recent years, the number of newborns surviving preterm birth has gradually increased due to advances in neonatal medicine. However, these rescues are not without consequences. Indeed, to do so, the child is separated from his parents, placed in a stressful, technical and potentially painful environment. This early separation is compounded by medical co-morbidities and sedations that compromise the child's physiology and availability to interact. Extreme prematurity also disrupts the early interactions between the child and his parents, and eventually the relationships with others. Thus, more than 35% of children born prematurely show insecure attachment behavior in their relationships with others. Moreover, premature births are accompanied by numerous somatic, cognitive and social cognitive difficulties. At school age, these children present more learning, social-emotional and behavioral problems. The greater the degree of prematurity, the more marked these difficulties are. They would be associated with an executive and social cognition deficit, inherent to a globally altered cerebral development, in particular the frontal subcortical cerebral regions. On the parents' side, premature birth is also fraught with consequences. Indeed, the idea of an idealized post-natal period gives way to an anxious, even traumatic experience. Notions of guilt are often expressed, as well as major anxiety about the child's survival and "parenting skills". A higher prevalence of signs of parental anxiety, postnatal depression and post-traumatic stress disorder is observed in mothers of premature infants, even up to 18 months after birth. These psychological states influence the parents' ability to interact with their newborn, as well as the content of these interactions. Finally, both parents and newborns see, for different reasons, their ability to interact and to reassure themselves profoundly disrupted by premature birth. Even if since 2010, prematurity has been identified as a "public health problem" by the WHO, studies on the subject still have limitations. Indeed, if we estimate that the prevalence of anxiety and/or depression signs in mothers of premature babies is on average three times higher than in mothers of full-term babies; what about fathers? It seems fundamental to improve our knowledge of the anxious and depressive symptoms that fathers and mothers of premature babies may display, with the aim of providing comprehensive and multidisciplinary care for families in neonatal intensive care units. Similarly, the exact impact of an increase in parental anxious depressive symptomatology on the precursors of cognitive and social cognitive development is not known. Since the environment and stimulation are fundamental to the child's development, what happens when one or both parents have their…

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Behavioral: State-Trait Anxiety Inventory - Y ou STAI-Y — Questionnaire

Primary Outcomes

  • STAI-Y : State Trait Inventory Anxiety - Y (week 7 weeks post partum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-28
Completion: 2028-05-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Reims
Contact Information
Study Contact:
Julien EUTROPE
3 26 78 94 76
jeutrope@chu-reims.fr
Damien JOLLY
326788472
djolly@chu-reims.fr
Chu Reims
Interventions
  • Behavioral: State-Trait Anxiety Inventory - Y ou STAI-Y — Questionnaire
Study Locations (1 sites)
Chu Reims, Reims, 51092 France
Eligibility Criteria
Inclusion Criteria: Children and their parents will be included in the study in the exposed group if: * the infant is born preterm, i.e., between 32 weeks of amenorrhea (SA) and 36 SA + 6 days. * at the maternity ward of the University Hospital of Reims * the parents are older than 18 years. * parents are affiliated to a social insurance. * parents agreed to participate in the study, within 72 hours after birth Will be included in the study, in the non-exposed group, children and their parents, if: * the children is born at term, i.e., from 37 SA + 0 Days * at the maternity ward of the Reims University Hospital * parents are older than 18 years. * parents are affiliated to a social insurance. * parents agreed to participate in the study, within 72 hours after birth Exclusion Criteria: Will not be included in the study, children and their parents, if: * the infant is born from multiple pregnancy * the infant is hemodynamically unstable * the birth occured more than 72 hours ago * the infant is affected by congenital malformations * the infant is affected by severe brain lesion detected by transfontanellar ultrasound scan performed before inclusion (cystic leukomalacia, and stages III and IV of the Papille classification i.e. severe ventricular dilatation or intra-parenchymal hemorrhage) * separation from the parents and placement of the child is intended * child is born anounymously * parents with psychiatric disorders * if the mother is suffering from hemodynamic compromise * parents under guardianship * parents non-native speaking
Conditions Lactation, Mindfulness, NICU, Breastmilk...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to investigate associations between mindfulness and meditation techniques and changes in maternal breastmilk in the mother pumping for her NICU infant.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Standard of Care — No additional session with the lactation consultant will be provided beyond the standard of care lactation admission visit with a lactation consultant within 72 hours of their infant's admission to the NICU. On days 0, 10 and 20, participants will be asked to record pumping session times and breastmilk volumes expressed for 24 hours, collect salivary oxytocin sample and salivary cortisol sample at minute 4 of one pumping session, and fill out the GAD7, PSS, and PHQ-8 surveys.
  • Behavioral: Mindfulness-based Intervention — In addition to the standard of care lactation admission visit, participants will receive an additional session with the lactation consultant for mindfulness-based lactation education. Participants will also be provided with a pumping meditation audio recording that they will be asked to listen to at least once daily for the next 20 days. On days 0, 10 and 20, participants will be asked to record pumping session times and breastmilk volumes expressed for 24 hours, collect salivary oxytocin sample and salivary cortisol sample at minute 4 of one pumping session, and fill out the GAD7, PSS, and PHQ-8 surveys. In addition, the intervention group participants will also be asked to record the number of times they listened to the recording daily, minutes listened to recording daily, and time of day listened to recording.

Primary Outcomes

  • Change in breastmilk volume (Baseline, 10 days, 20 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-22
Completion: 2026-11-02
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Ashley Thompson (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Ashley Thompson, BSN, RN, IBCLC
507-422-5523
NICULactationStu@mayo.edu
Mayo Clinic in Rochester
Tawney DeBoth, BSN, RN, IBCLC
507-422-5523
NICULactationStu@mayo.edu
Mayo Clinic in Rochester
Ashley Elizabeth Thompson, BSN, RN, IBCLC
Mayo Clinic in Rochester
Interventions
  • Behavioral: Standard of Care — No additional session with the lactation consultant will be provided beyond the standard of care lactation admission visit with a lactation consultant within 72 hours of their infant's admission to the NICU. On days 0, 10 and 20, participants will be asked to record pumping session times and breastmilk volumes expressed for 24 hours, collect salivary oxytocin sample and salivary cortisol sample at minute 4 of one pumping session, and fill out the GAD7, PSS, and PHQ-8 surveys.
  • Behavioral: Mindfulness-based Intervention — In addition to the standard of care lactation admission visit, participants will receive an additional session with the lactation consultant for mindfulness-based lactation education. Participants will also be provided with a pumping meditation audio recording that they will be asked to listen to at least once daily for the next 20 days. On days 0, 10 and 20, participants will be asked to record pumping session times and breastmilk volumes expressed for 24 hours, collect salivary oxytocin sample and salivary cortisol sample at minute 4 of one pumping session, and fill out the GAD7, PSS, and PHQ-8 surveys. In addition, the intervention group participants will also be asked to record the number of times they listened to the recording daily, minutes listened to recording daily, and time of day listened to recording.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Maternal age \> 20 years of age * Read, write and understand English * Infant NICU admit * Infant birthplace of Rochester, MN (Mayo Clinic) * Maternal adherence to pumping ≥ 8 times in 24 hours * Mother enrolled within 72 hours of birth * Gestational age of neonate at birth of \< 34 0/7 weeks Exclusion Criteria: * Maternal extensive existing mindfulness practice * Maternal breast/chest surgery * Maternal polycystic ovarian syndrome (PCOS) * Maternal current illicit substance abuse * Diagnosis of maternal current severe mental health concerns * Maternal multiple gestation (twins or higher order) pregnancy and delivery
Conditions Depression, Sequestra
Phase PHASE1, PHASE2
Enrollment 520
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Fluoxetine — Commonly used oral antidepressant.
  • Drug: Sertraline — Commonly used oral antidepressant.
  • Drug: Vortioxetine — Commonly used oral antidepressant.
  • Drug: Duloxetine — Commonly used oral antidepressant.
  • Drug: Aripiprazole — Commonly used oral augmentation therapy for antidepressants
  • Drug: Lithium Carbonate — Commonly used oral augmentation therapy for antidepressants.
  • Drug: Olanzapine — Commonly used oral augmentation therapy for antidepressants.
  • Behavioral: GCBT — Commonly used intervention therapy of psychotherapy.

Primary Outcomes

  • Change in CDRS-R (Children's Depression Rating Scale) scores from baseline (Baseline of treatment period, 2 weeks, 1 month, 2 months, 3 months,4months; The follow-up period was 1 month, 3 months, 6 months and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-02-20
Completion: 2027-07-01
Eligibility
Age: 13 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 520 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Chongqing Medical University
Collaborators: The Second Affiliated Hospital of Chongqing Medical University, Second Xiangya Hospital of Central South University, Children's Hospital of Chongqing Medical University
Contact Information
Study Contact:
Xinyu Zhou
15823996993
zhouxinyu@cqmu.edu.cn
Zhou Xinyu, Doctor of Philosophy
15823996993
zhouxinyu@cqmu.edu.cn
The First Affiliated Hospital of Chongqing Medical University
Interventions
  • Drug: Fluoxetine — Commonly used oral antidepressant.
  • Drug: Sertraline — Commonly used oral antidepressant.
  • Drug: Vortioxetine — Commonly used oral antidepressant.
  • Drug: Duloxetine — Commonly used oral antidepressant.
  • Drug: Aripiprazole — Commonly used oral augmentation therapy for antidepressants
Study Locations (1 sites)
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province 400000 China
Eligibility Criteria
Inclusion Criteria: 1. Age 13 - 18 2. As assessed by K-SADS-PL, it meets the DSM-V criteria for MDD with non-psychotic symptoms 3. Score≥40 on the CDRS-R 4. Participants with suicidal ideation are eligible, as long as clinicians consider outpatient treatment to be safe 5. Sufficient audio-visual level to complete this study 6. Written informed consent was obtained from patients and at least one of their parents Exclusion Criteria: 1. History of bipolar disorder, schizophrenia, autism, eating disorders, primary obsessive compulsive disorder, pervasive developmental disorder, or psychosis not otherwise specified 2. History of serious physical illnesses 3. Substance abuse or dependence 4. Current depressive episode with clear suicidal plans or suicidal behavior 5. Requires inpatient treatment for psychiatric disorders 6. Severe mental disorders requiring 7. 2 or more failed trials of antidepressant drugs: each trial for at least 8 weeks, with the last 4 weeks at full dose (e.g. fluoxetine 40mg/d, citalopram 40mg/d, escitalopram 20mg/d, sertraline 150mg/d ) 8. History of clear-cut intolerability of, or lack of effect with, an adequate trial of at least one protocol treatment option 9. Taking any medicine that contraindicates in combination with or interferes with the efficacy of the treatment 10. Taking or administering antidepressants within 5 half-lives 11. Received modified electroconvulsive therapy within 12 months 12. If female, is pregnant
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 164
Locations 32 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel1)? What medical problems are observed in participants who take zelquistinel? Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Zelquistinel — Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor

Primary Outcomes

  • Change in the Hamilton Depression Rating Scale-17 (HDRS-17) score compared to Placebo (Change in score from baseline to 6 wweeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-05
Completion: 2028-06
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 164 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Syndeio Biosciences, Inc
Collaborators: Worldwide Clinical Trials
Contact Information
Study Contact:
Karen Raudibaugh
781-786-1545
karen.raudibaugh@syndeio.bio
Sharon Ortiz
sharon.ortiz@syndeio.bio
John P
602-795-1834
jprater@noesispharma.com
NoesisPharma, LLC
Interventions
  • Drug: Zelquistinel — Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Study Locations (32 sites)
NoesisPharma, LLC, Phoenix, Arizona 85028 United States
Del Sol Research Management, Tucson, Arizona 85710 United States
Catalina Research Institute, LLC, Montclair, California 91763 United States
Excell Research, Inc, Oceanside, California 92056 United States
Anderson Clinical Research, Redlands, California 92374 United States
Studyops Inc, San Francisco, California 94102 United States
Lumos Clinical Research Center, San Jose, California 95124 United States
Sunwise Clinical Research, Walnut Creek, California 94596 United States
Clinical Neuroscience Solutions, Inc, Jacksonville, Florida 32256 United States
Premier Clinical Research Institute Inc, Miami, Florida 33122 United States
Eligibility Criteria
Inclusion Criteria: * Male or female subject. * Aged 18 to 64 years, inclusive. * Subject has a first episode or recurrent episode diagnosis of MDD, defined by the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), ≥3 weeks and ≤18 months. The diagnosis of MDD will be made by a central rater using the Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT). * Subject has a HDRS-17 total score of ≥18 at the Screening Visit (V1) and Baseline Visit (V2) as assessed by a central rater, with no more than a 25% change from the Screening Visit (V1) to the Baseline Visit (V2) * Subject has HARS total score ≥15 at the Screening Visit (V1) and predose at the Baseline Visit (V2), AND * Subject has ISI total score ≥10 at the Screening Visit (V1) and predose at the Baseline Visit (V2). * Female subjects must meet 1 of the following: * Surgically sterile or at least 2 years menopausal (ie, postmenopausal is defined as a woman with the absence of menses for at least 12 consecutive months). Menopausal status is to be confirmed by assessing the follicle stimulating hormone level at Screening Visit (V1), or, * If a woman of childbearing potential, subject must use an acceptable method of birth control from date of Screening to the last evaluation at Day 71. Must have a documented negative point of care urine pregnancy test within 24 hours prior to first dosing. * Male subjects, including those who are surgically sterile, must use a medically acceptable form of contraception from the time of randomization until the End of Week 6 Visit. Male subjects are strongly advised to inform female partners of the need for them to use highly effective birth control during this time period. * Ability to understand the nature and requirements of the study and is willing to comply with the study restrictions and agree to return for the required assessments. * Provides written informed consent to participate in the study. * Is able to communicate with investigational site personnel, able to complete patient-reported outcome measures and in the opinion of the Investigator, can be reliably rated on assessment scales. * Have an appropriate severity of illness of at least moderately ill corresponding to a CGI-S score of ≥4 at the Screening and Baseline Visits (V1 and V2, respectively), as assessed by a central rater. Exclusion Criteria: * A subject who meets any of the following criteria will be excluded from study participation: * Evidence of treatment-resistant MDD, defined by having an inadequate response (≤25%) to 2 or more different medications approved for the treatment of MDD at an adequate dose (per locally approved label) for an adequate duration during the current episode using the Massachusetts General Hospital Antidepressant Treatment Rating Questionnaire (MGH ATRQ) assessed by a site rater. * Current DSM-5 diagnosis of bipolar (or related disorders), antisocial personality disorder, obsessive compulsive disorder, borderline personality disorder,attention-deficit/ hyperactivity disorder, post-traumatic stress disorder, or panic attacks. Subjects not meeting full DSM-5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded. * Subject has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features. * Subject has a score of \>4 on the CADSS at the Screening Visit (V1). * Active seizure disorder. * Traumatic brain injury with current signs or symptoms. * Treatment with esketamine or ketamine, any psychedelic agent, or any experimental agent being evaluated to treat depression, whether as an antidepressant or for other use, within the past 12 months. o Treatment with any other experimental agents not used to treat depression within the past 3 months. * Concomitant treatment with other Food and Drug Administration (FDA)-approved antidepressants or adjuvant agents or enhancers such as dextromethorphan, antipsychotics, mood stabilizers, sedatives, stimulants, or benzodiazepines. Subject must discontinue concomitant treatment at least 14 days prior to the Baseline Visit. o Subjects may continue anxiolytic agents, except for drugs that are also used to treat depression. Subjects may continue sleep aids, so long as they have been on a stable dose for at least 3 months and do not intend to change dose during the Double-Blind Treatment Period (Week 1 \[Day 1\] through End of Week 6). However, trazodone must be discontinued for at least 14 days prior to the Baseline Visit. * Use of cannabis or cannabis-derived molecules, including tetrahydrocannabinol (THC), whether natural or chemically-synthesized, including hemp seed oil and cannabidiol (CBD) products (eg, gummies). Subject must discontinue the use of such products at least 14 days prior to the Baseline Visit, and THC must be below the limit of detection at the Baseline Visit. * Positive test for any drug of abuse. * Treated with any medical device or digital therapeutics for MDD, anxiety, insomnia, or other CNS indications within 90 days of screening in this study. * History of electroconvulsive therapy, vagus nerve stimulation, deep brain stimulation, or repetitive transcranial magnetic stimulation within the past 5 years or has had a failure of response to electroconvulsive therapy at any time. * Subject has clinically significant renal dysfunction as assessed by the estimated glomerular filtration rate (eGFR) \<70 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration-creatinine (CKD-EPI creatinine) methodology. * Subject has liver protein and enzyme (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, total bilirubin, lactate dehydrogenase) test result \>1.5 × upper limit of normal (subjects with a diagnosis of Gilbert's Syndrome may be eligible if no liver function or enzyme test results other than total bilirubin are \>1.5 × upper limit of normal). * Subject has resting radial pulse rate (supine) \<60 or \>100 bpm at the Screening Visit or predose Baseline, based on a single assessment. * Subject has resting diastolic blood pressure \<50 mmHg at the Screening Visit or predose Baseline. * Subject has PR interval \>250 msec at the Screening Visit or predose Baseline, or QT corrected for heart rate by Fridericia's formula (QTcF) or QT corrected for heart rate by Bazett's formula (QTcB) interval \>450 msec in males or \>470 msec in females, or QRS interval \>120 msec, based on a single reading. * Evidence of alcohol abuse (\>4 units of alcohol on most days; 1 unit=½ pint of beer, 1 glass of wine, or 1 ounce of hard liquor/spirits) or a positive saliva alcohol screen at Screening and predose at the Baseline Visit. Alcohol consumption should be avoided for at least 24 hours prior to Baseline Visit. * Abuse of illicit substances by DSM-5 definition of substance use disorder within the 12 months prior to the Screening Visit. * Use of nicotine containing products (eg, cigarettes, cigars, vaping, and pipes). Nicotine containing products must be discontinued for at least 14 days prior to randomization, and nicotine or cotinine (metabolite) must be negative at Baseline. * Use of barbiturates. Prescribed barbiturates may be continued so long as the subject has been on a stable dose for at least 3 months and the dose may not change during the Double-Blind Treatment Period. * HIV infection, COVID-19 infection,or active hepatitis B or C, syphilis, or other ongoing infectious disease at the Screening Visit (V1). * Has laboratory evidence of hypothyroidism at Screening Visit (V1) as measured by thyroid stimulating hormone (TSH) and reflex free thyroxine (T4). If TSH is abnormal and reflex T4 is normal, the subject may be included. * Has current unstable diabetes or glycosylated hemoglobin (HbA1c) \>7% at Screening Visit (V1). * Currently pregnant, planning to become pregnant during the course
Conditions Depression, Bipolar Disorder, Recurrent ...
Phase NA
Enrollment 588
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Depression and bipolar disorder are frequent, debilitating conditions. Both are thought to be primarily caused by an impaired regulation of mood, which is why they are sometimes referred to as "mood disorders". However, the biological basis of mood remains poorly understood, which is a major limitation for the development of new treatments. Recent work that combines neuroscience with mathematical models are promising to better understand mood and to link it to its biological basis, but they don't have any medical application yet. Can these models describe mood in a way that is relevant to mood disorders, and help doctors and psychologists predict subsequent clinical evolution? With the objective of extending this framework to real-life fluctuations and to assess its clinical relevance, this study will combine a neuroimaging session with a smartphone-based, longitudinal follow-up. Three groups of 96 subjects each will be recruited: depressive disorder, bipolar disorder and healthy controls. They will have their mood fluctuations assessed first in the lab (in the neuroimaging experiment), then in their daily lives (by providing a few ratings and choices every day on the smartphone app). This study will allow to better understand the differences in how patients' mood reacts to daily events, as compared to people who don't suffer from depression or bipolar disorder. The combination of the two steps will allow to assess whether a short neuroimaging evaluation can be useful to predict subsequent clinical evolution during the following months. The investigators wanted to add two optional ancillary studies. The first uses a mobile application for implicit, passive, and longitudinal mood assessments through emotion tracking. Indeed, it seems relevant to add this type of evaluation alongside explicit assessments to more accurately detect mood fluctuations. The second study uses a mobile application that allows voice recordings. The analysis of these vocal parameters will help to characterize a specific linguistic and vocal profile within the three groups, as well as to identify specific symptoms of conditions such as depression and bipolar disorder. These ancillary studies will be offered to both patients and the control group.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Brain magnetic resonance imaging (MRI) with structural (anatomical) and functional sequences (optional) — Brain MRI with structural (anatomical) and functional sequences (without contrast injection) will be collected. The cognitive tests will be carried out during the recording of the functional MRI (optional) in order to highlight the neural correlates of mood variations.
  • Behavioral: Computerized cognitive tests — Cognitive tests can be administered during the recording of a functional MRI, in order to highlight the neural correlates of mood variations. Cognitive data from a computerized experimental psychology experiment: this test involves different tests on a computer or tablet, including a test evaluating the minimal variations in the subject's mood and motivational state during the task, as well as its decision-making abilities.
  • Device: Daily longitudinal monitoring by mobile MOODELING application — Daily longitudinal monitoring by mobile MOODELING application (mood, energy, events) with self-monitoring tools (calendar, mood curve) at home. Follow-up duration on the application: 12 months

Primary Outcomes

  • Computational phenotypes of daily mood fluctuations in the 3 groups (From enrolment to Month 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-18
Completion: 2029-07-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 588 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier St Anne
Collaborators: Paris Brain Institute (ICM)
Principal Investigators:
  • Fabien Vinckier, Dr (PRINCIPAL_INVESTIGATOR) - GHU Paris Psychiatry & Neurosciences
Contact Information
Study Contact:
Fabien Vinckier, Pr
(0) 1 45 65 84 52
F.VINCKIER@ghu-paris.fr
Fabien Vinckier, Pr
- Groupe hospitalo-universitaire Paris Psychiatrie et Neurosciences
Philippe FOSSATI, Pr
0142162870
philippe.fossati@aphp.fr
Assistance Publique - Hôpitaux de Paris GH Pitié-Salpêtrière
Interventions
  • Diagnostic Test: Brain magnetic resonance imaging (MRI) with structural (anatomical) and functional sequences (optional) — Brain MRI with structural (anatomical) and functional sequences (without contrast injection) will be collected. The cognitive tests will be carried out during the recording of the functional MRI (optional) in order to highlight the neural correlates of mood variations.
  • Behavioral: Computerized cognitive tests — Cognitive tests can be administered during the recording of a functional MRI, in order to highlight the neural correlates of mood variations. Cognitive data from a computerized experimental psychology experiment: this test involves different tests on a computer or tablet, including a test evaluating the minimal variations in the subject's mood and motivational state during the task, as well as its decision-making abilities.
  • Device: Daily longitudinal monitoring by mobile MOODELING application — Daily longitudinal monitoring by mobile MOODELING application (mood, energy, events) with self-monitoring tools (calendar, mood curve) at home. Follow-up duration on the application: 12 months
Study Locations (2 sites)
- Groupe hospitalo-universitaire Paris Psychiatrie et Neurosciences, Paris, Paris 75014 France
Assistance Publique - Hôpitaux de Paris GH Pitié-Salpêtrière, Paris, 75651 France
Eligibility Criteria
Inclusion Criteria: Common between groups (DD, BD, control and GP): * Having given informed and written consent * Being covered by social security For patients with depressive disorder (DD): * Having been diagnosed with characterized depressive episode (F32, F33, F34) according to the ICD-10, by a psychiatrist, or having presented this diagnosis during the past 12 months For patients with bipolar disorder (BD): * Presenting a diagnosis of bipolar mood disorder (F31) according to ICD-10, by a psychiatrist * Having presented a mood episode (F31.0 - F31.6) diagnosed during the past 12 months by a psychiatrist Exclusion Criteria: Common between groups (DD, BD, control and GP): * Inability to carry out daily monitoring on mobile application for 12 months * legal protection measure (guardianship or curatorship) For control group: * Current diagnosis of psychiatric disorder in ICD-10 (F20-F98) or prescription of psychotropic treatment * History of depression (F32) * Syndrome of dependence on a psychoactive substance other than tobacco * Neurological history (in particular history of stroke, coma, epilepsy, neuro- inflammatory, or neuro-degenerative disease) * Inability to carry out daily monitoring on mobile application for 12 months For patients and healthy volunteers for whom an MRI (without injection of contrast agent) is proposed * Contraindication to MRI: cardiac pacemaker not compatible with MRI, heart valve implant, implant or metallic foreign body * Pregnant woman (at the time of MRI)
Conditions Major Depressive Disorder
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a common illness that can affect a person's mood, sleep, energy, ability to work, and overall quality of life. While medicines are available to treat depression, many people do not get complete relief from their symptoms. This study will evaluate whether adding a magnesium supplement in the form of magnesium bisglycinate to regular antidepressant treatment can help improve symptoms of depression. Adults with depression who are already receiving treatment will be randomly assigned to receive either magnesium bisglycinate or a placebo (an inactive substance) along with their usual medication. The study will compare the two groups to see whether the supplement leads to greater improvement in symptoms, sleep, and day-to-day functioning. Information on any side effects will also be collected. The findings may help determine whether magnesium bisglycinate can be used as a safe and affordable additional treatment for people with depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Magnesium Bisglycinate — Magnesium Bisglycinate (220 mg elemental mangnesium and 1350 mg glycine) per day for 8 weeks
  • Other: Microcrystalline cellulose — The placebo capsules will contain Microcrystalline cellulose (inactive excipient) and will be of similar colour, shape and size as of magnesium bisglycinate capsules and will be given once daily for 8 weeks.

Primary Outcomes

  • Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score (Baseline (week 0) and follow-up (week 8))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-12
Completion: 2028-06-12
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Principal Investigators:
  • Debasish Hota, D.M. (STUDY_CHAIR) - AIIMS, Bhubaneswar
Contact Information
Study Contact:
Rituparna Maiti, M.D.
9438884191
pharm_rituparna@aiimsbhubaneswar.edu.in
RITUPARNA MAITI, MD
9438884191
rituparnamaiti@gmail.com
All India Institute of Medical Sciences (AIIMS)
BISWA R MISHRA, MD
brm1678@gmail.com
All India Institute of Medical Sciences (AIIMS)
Interventions
  • Dietary Supplement: Magnesium Bisglycinate — Magnesium Bisglycinate (220 mg elemental mangnesium and 1350 mg glycine) per day for 8 weeks
  • Other: Microcrystalline cellulose — The placebo capsules will contain Microcrystalline cellulose (inactive excipient) and will be of similar colour, shape and size as of magnesium bisglycinate capsules and will be given once daily for 8 weeks.
Study Locations (1 sites)
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha 751019 India
Eligibility Criteria
Inclusion Criteria: 1. Patients with a diagnosis of Major Depressive Disorder (MDD) as per DSM-5 criteria. 2. Patients of either sex within the age group of 18-65 years. 3. Mild to severe depression, defined as a baseline MADRS score ≥7. 4. Currently receiving a stable dose of antidepressant monotherapy (SSRI or SNRI) in equivalent doses. 5. Willing and able to provide written informed consent. Exclusion Criteria: 1. Known hypersensitivity or allergy to magnesium supplements or glycine. 2. History of renal impairment (previous history of AKI, CKD, currently on dialysis). 3. Diagnosis of bipolar affective disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder. 4. Active suicidal ideation with intent or a recent suicide attempt (within the past 6 months), as assessed by the treating psychiatrist. 5. Current substance use disorder (except nicotine, alcohol and caffeine), as per DSM-5 criteria. 6. Pregnancy, lactation, or women of childbearing potential not using adequate contraception. 7. Concurrent use of magnesium-containing supplements, antacids, or laxatives. 8. History of significant severe medical comorbidity, including uncontrolled hypothyroidism, Cushing's syndrome, active malignancy, myasthenia gravis, or severe hepatic impairment. 9. Use of medications with significant pharmacokinetic interactions with magnesium (e.g., tetracyclines, fluoroquinolones, bisphosphonates, diuretics) that cannot be temporally separated by ≥2 hours. 10. Electroconvulsive therapy (ECT) received within the past 3 months.
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Dialectical behavior therapy (DBT) is a comprehensive, third-wave psychological intervention designed for patients with complex and severe behavioral, emotional, and interpersonal dysfunction. DBT has since been adapted to shorter, briefer, "skills training" formats, which have been effective for a number of mild-to-moderate mental health conditions, including depression and anxiety. Moreover, internet-delivered formats of DBT (iDBT) have similarly started to build support for their effectiveness, although there are fewer studies on digital formats. One study found that over 12 weeks, iDBT was deemed acceptable (e.g., 50% of participants were still active after 4 weeks) and there were improvements in multiple symptom domains, such as depression, anxiety, suicidality, functional disability, as well as alcohol and substance dependence. In the current study, the investigators will examine the feasibility, acceptability, and potential efficacy of a new iDBT intervention, packaged as an online e-learning skills course, with adult participants. The study is a pilot trial as iDBT has never been tested in this format through formal research. Thus, this pilot study aims to examine whether this course is usable, practical, and potentially useful to others in the future. The investigators will recruit up to 40 individuals with mild-to-moderate depression and anxiety for an 8-week study. Following a phone screen to determine eligibility, participants will complete a baseline session where they will provide consent, complete a brief interview and questionnaires, and register for the e-learning skills course. Over the course of 8 weeks, participants will be exposed to material adapted from a DBT manual in a self-guided manner. Participants will complete follow-up assessments at 4 and 8 weeks.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: dialectical behavior therapy — This internet-delivered dialectical behavior therapy (iDBT) intervention consists of an e-learning course with 4 modules based on the 4 areas of skills training in dialectical behavior therapy: mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Participants can work through the modules at a self-guided pace to learn more than 30 specific skills using psychoeducational materials. The intervention incorporates psychoeducational elements of skills training with introductory videos, interactive quizzes, practice and homework suggestions, as well as quotes and videos from individuals with lived experience. In preliminary testing, it was estimated to take approximately 8-10 hours to complete all material.

Primary Outcomes

  • Treatment Acceptability and Adherence Scale (4 weeks and 8 weeks)
  • Intervention Usability Scale (4 weeks and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-20
Completion: 2026-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Windsor
Contact Information
Study Contact:
Alexander Daros, Ph.D., C.Psych.
519-253-3000
alexd1@uwindsor.ca
Riad El-karout
dbtresearch@uwindsor.ca
Alexander Daros, Ph.D., C.Psych.
519-253-3000
alexd1@uwindsor.ca
University of Windsor
Interventions
  • Behavioral: dialectical behavior therapy — This internet-delivered dialectical behavior therapy (iDBT) intervention consists of an e-learning course with 4 modules based on the 4 areas of skills training in dialectical behavior therapy: mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Participants can work through the modules at a self-guided pace to learn more than 30 specific skills using psychoeducational materials. The intervention incorporates psychoeducational elements of skills training with introductory videos, interactive quizzes, practice and homework suggestions, as well as quotes and videos from individuals with lived experience. In preliminary testing, it was estimated to take approximately 8-10 hours to complete all material.
Study Locations (1 sites)
University of Windsor, Windsor, Ontario N9B 3P4 Canada
Eligibility Criteria
Inclusion Criteria: * Ages 18 years old and up. * Reside in Ontario. * Fluent in English. * Able to provide autonomous informed consent * Reports at least mild depression and/or anxiety symptoms * Not currently receiving any psychotherapy or psychosocial interventions. * Have access to the internet Exclusion Criteria: * Practical (e.g., scheduling), acute psychiatric (e.g., suicidal ideation nearly every day, recent hospitalization for mental health reasons), or medical reasons (e.g., upcoming surgery, medical procedure, head injury). * Not meeting one or more of the above inclusion criteria
Conditions Chronic Pain, Musculoskeletal Pain, Depr...
Phase NA
Enrollment 304
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/). This randomized controlled trial (RCT) is phase 2 of a two-phase, 5-year project with the overarching goal of testing a decision aid (DA)/coaching intervention, tailored to Black patients with comorbid chronic pain and depression, to encourage use of and adherence to nonpharmacological pain treatments (NPTs). This 2-arm trial will randomize 304 patients with comorbid chronic musculoskeletal pain and depression in primary care from an urban safety-net health system (Eskenazi). After the baseline assessment, patients randomized to the intervention will be asked to participate in 4 coaching sessions over approximately 12 weeks. Sessions will use Motivational Interviewing principles to foster openness to NPTs and self-efficacy by helping patients identify their goals and priorities, understand their NPT options, prepare them to discuss and choose options with their primary care providers (PCPs), and reinforce these choices to foster maintenance of these changes. DA contents will be integrated into these sessions, which will facilitate discussion of these options with their PCP. The first 3 sessions take place prior to the patient's next scheduled PCP visit; the final session occurs after this visit. Assessments will be conducted at baseline, 3 months (i.e., after completing the final coaching session), and 6 months. Patients randomized to the wait-list control group will receive usual care (in addition to study assessments at baseline, 3 months, and 6 months). After completing the final assessment, they will then be given the DA and offered a 20-minute coaching session to walk them through it.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Coaching and Decision Aid — Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents

Primary Outcomes

  • Change from Baseline Brief Pain Inventory (BPI) Interference Scale at 3 months (3 months)
  • Change from Baseline Brief Pain Inventory (BPI) Interference Scale at 6 months (6 months)
  • Change from Baseline Patient Health Questionnaire (PHQ)-8 at 3 months (3 months)
  • Change from Baseline Patient Health Questionnaire (PHQ)-8 at 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-13
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 304 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Indiana University
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Adam T Hirsh, PhD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Research Specialist
317-274-9402
equipd@regenstrief.org
Jennifer Garabrant
317-278-2510
jwilkers@iu.edu
Research Specialist
317-274-9402
equipd@regenstrief.org
Eskenazi Health Primary Care
Interventions
  • Behavioral: Coaching and Decision Aid — Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
Study Locations (1 sites)
Eskenazi Health Primary Care, Indianapolis, Indiana 46254 United States
Eligibility Criteria
Inclusion Criteria: Eligible patients must * have musculoskeletal pain in the low back, cervical spine, or extremities (hip, knee, shoulder) for ≥3 months, * have at least moderate pain intensity and interference with function, defined by a score ≥4 (possible range: 0-10) on the Pain, Enjoyment of Life and General Activity scale (PEG), a 3-item measure of pain intensity, interference with enjoyment of life, and interference with general activity, * have at least mild depression, defined as PHQ-8 score ≥5, * identify as Black or African American, * have consistent access to a telephone, * indicate openness to new pain treatments, and * have a scheduled appointment with their PCP in the next approximate 2-4 months or be willing to schedule one Exclusion Criteria: Patients are excluded: * if previously participated in Dr. Matthias' past pilot study (IRB #12885), the pilot RCT for this project (IRB #16571), or are participating as a Patient Engagement Panel member for this project (Aim 1.1), * if the eligibility screener or medical records indicate severe medical conditions likely precluding participation (e.g. stroke in the last 6 months, hospitalized with congestive heart failure or a heart attack in the last 6 months, cancer other than skin cancer and receiving active treatment), or * if the eligibility screener or medical records reveal (1) active suicidal ideation, or (2) severe hearing/speech or cognitive impairment.
Conditions Emotional Disorders, Anxiety, Depression...
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to evaluate the effectiveness and underlying processes of change of the Unified Protocol (UP) for treating emotional disorders in a university outpatient clinic. The study will involve 140 patients receiving UP treatment in a group format, delivered either by experienced or novice therapists, along with a non-clinical control group of 45 participants. Participants will self-refer on the basis of advertisement about the study through flyers, posters, project website, social media or local news media. Outcomes will be assessed through self-report measures of well-being, symptoms, emotion regulation, and the non-specific factors of treatment credibility and therapeutic alliance. Additionally, psychophysiological measures of heart rate variability and interoception will be used to explore processes influencing treatment response. Qualitative interviews will complement the quantitative data by capturing participants' perspectives on the treatment and experiences of what contributed to change.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Unified Protocol — The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format

Primary Outcomes

  • WHO-5: Wellbeing index (From enrollment to follow-up at 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-08
Completion: 2034-12
Eligibility
Age: 18 Years – 40 Years
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bergen
Principal Investigators:
  • Jon Vøllestad, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Bergen
Contact Information
Study Contact:
Jon Vøllestad, Ph.D.
0047 95 21 32 86
jon.vollestad@uib.no
Elisabeth Schanche, Ph.D.
0047 97 77 42 17
elisabeth.schanche@uib.no
Jon Vøllestad, Ph.D.
0047 95 21 32 86
jon.vollestad@uib.no
Department of Clinical Psychology
Interventions
  • Behavioral: Unified Protocol — The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format
Study Locations (1 sites)
Department of Clinical Psychology, Bergen, Vestland 5009 Norway
Eligibility Criteria
Inclusion Criteria: * Age 18-40 * Fulfilling diagnostic criteria for an anxiety disorder and/or unipolar depression (ICD F.3x - 4x) * Motivated for short-term treatment in group format Exclusion Criteria: * Suicidality * Self-harm * Severe psychiatric disorder (bipolar disorder, psychosis) * Substance use disorders * Use of anxiolytic medication (i.e., benzodiazepines) * Unstable antidepressant medication (i.e., stable dosage \<6 months) * Other ongoing psychological treatment
Conditions Chemotherapy Induced Peripheral Neuropat...
Phase PHASE2, PHASE3
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this phase II/III randomized clinical trial is to evaluate the effect of adding rectal ozone therapy to the usual management of patients with paresthesia (numbness and/or tingling) due to chemotherapy-induced peripheral neuropathy (CIPN). Ozone treatment consists of the rectal insufflation of 180 - 300 milliliters of an ozone/oxygen gas mixture. The main questions to answer are: 1. Can ozone therapy improve patients' self-perceived level of numbness and tingling? 2. Can ozone therapy improve patients' self-perceived health-related quality of life (HRQoL)? In 42 patients with chronic numbness and tingling secondary to chemotherapy, the researchers will compare: * the addition of rectal ozone insufflations * versus the addition of rectal oxygen insufflations (placebo). Participants will receive 40 rectal gas (ozone versus oxygen) insufflations in 16 weeks and will continue other symptomatic or cancer treatments prescribed by their oncologists. Before treatment, after treatment, and 12 weeks after treatment, they will be evaluated: * Several questionnaires about neuropathy, quality of life, and anxiety and depression. * Biochemical parameters of oxidative stress and inflammation * Hyperspectral images of hands and feet * Toxicity of procedure.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Ozone therapy — Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
  • Drug: Oxygen (placebo) — Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

Primary Outcomes

  • Change from baseline in "numbness and tingling" self-perceived by patients at the end of follow-up (week 28 after the commencement of ozone treatment) (28 weeks)
  • Change from Baseline in quality of life by the EQ-... (28 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2025-02-07
Completion: 2030-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bernardino Clavo, MD, PhD
Collaborators: Council of Gran Canaria, Centers for International Business Education and Research, Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Complejo Hospitalario Universitario Insular Materno Infantil, Servicio Canario de Salud, University of Las Palmas de Gran Canaria, Instituto de Salud Carlos III
Principal Investigators:
  • Bernardino Clavo, MD, PhD (STUDY_CHAIR) - Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • Francisco Rodríguez-Esparragón, BSc, PhD (STUDY_DIRECTOR) - Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • Himar Fabelo, BSc, PhD (PRINCIPAL_INVESTIGATOR) - Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
Contact Information
Study Contact:
Bernardino Clavo, MD, PhD
34928449278
bernardinoclavo@gmail.com
Francisco Rodríguez-Esparragón, BSc, PhD
34928449288
afrodesp@gmail.com
Bernardino Clavo, MD, PhD
34928449278
bernardinoclavo@gmail.com
Dr. Negrín University Hospital
Interventions
  • Drug: Ozone therapy — Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
  • Drug: Oxygen (placebo) — Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study Locations (1 sites)
Dr. Negrín University Hospital, Las Palmas, Las Palmas 35019 Spain
Eligibility Criteria
Inclusion Criteria: * 1\. Adults \> = 18 years old. * 2\. Previous treatment with any chemotherapy because of any tumor. * 3\. Clinical diagnosis of paresthesia (numbness, tingling) secondary to CIPN, with toxicity Grade \> = 2 (according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0) for \> = 3 months. * 4\. Without neurotoxic chemotherapy \> = 3 months. * 5\. Cancer disease is stable or in remission. * 6\. Life expectancy \> = 6 months. * 7\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from 14 days before the first ozone therapy session up to 14 days after the last one. * 8\. To sign and date the study-specific informed consent Exclusion Criteria: * 1\. Age \< 18 years. * 2\. A woman who is lactating, pregnant, suspected of being pregnant, or a woman of childbearing potential who does not use adequate contraceptive methods. * 3\. Suspected symptoms are due to diabetic or compressive neuropathy. * 4\. Severe psychiatric disorders. * 5\. Inability to complete the quality of life questionnaires. * 6\. Elevation above 5 times the maximum limit of normal creatinine. * 7\. Patient who is hemodynamic or clinically unstable or who requires urgent or short-term interventional measures. * 8\. Neoplasia in progression requiring recent initiation of systemic treatment or maintenance with neurotoxic chemotherapy. * 9\. Life expectancy (for any reason) \< 6 months. * 10\. Known allergy to ozone, known glucose 6 phosphate dehydrogenase (G6PD) deficiency, or hemochromatosis. * 11\. Contraindications or impossibility for rectal ozone treatment or to attend regularly to the treatment. * 12\. Not meeting each and every one of the inclusion criteria